Hematology
Conference Coverage
EHR-based thromboembolism risk tool boosted prophylaxis
A thromboembolism risk calculator in a hospital’s EHR led to a significant rise in appropriate thromboprophylaxis and a drop in thromboembolic...
Latest News
Children with sickle cell anemia not getting treatments, screening
Annual screenings are recommended as is treatment with hydroxyurea, but only about half of affected children are getting lifesaving care.
Latest News
AAP guidance helps distinguish bleeding disorders from abuse
Laboratory testing of bleeding cannot always rule out abuse, just as a history of trauma may not rule out a bleeding disorder or other medical...
News
Blood type linked to higher risk for early onset stroke
“The risk of stroke due to blood type is smaller than other risk factors that we know about, like smoking and hypertension. I would be much more...
Conference Coverage
AXIOMATIC-SSP: Cautious optimism on factor XI inhibitor in stroke
The new factor XI inhibitor antithrombotic, milvexian, showed promising results in a dose-finding phase 2 trial in patients with acute ischemic...
News
Updated AHA/ASA guideline changes care for spontaneous intracerebral hemorrhage
Several “standard care” therapies for ICH are not as effective as once thought and are no longer recommended in updated guidelines.
From the Journals
Cancer patients unaware of their increased thrombosis risk
“These professionals are on the front line of the battle; they are among the first healthcare workers given the chance to suspect a clot and...
From the Journals
Corticosteroids may raise risk of sickle cell pain crisis
“Vaso-occlusive events and related hospitalization appear to follow corticosteroid prescription fairly quickly.”
Feature
CVS Caremark formulary change freezes out apixaban
The decision doesn’t affect patients on a Medicare or Medicaid plan but hits those taking the popular anticoagulant who have select commercial...
News from the FDA/CDC
CDC panel backs mRNA COVID vaccines over J&J because of clot risk
The risk of dying from TTS after a Johnson & Johnson shot is extremely rare.
From the Journals
Antithrombotic therapy not warranted in COVID-19 outpatients
In stable patients with COVID-19, use of aspirin or apixaban did not reduce the rate of the composite of all-cause mortality, thromboembolism, MI...